Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical leader developing targeted protein degradation therapies for cancer and immune disorders. This page provides centralized access to official news and press releases, offering critical insights into the company’scientific advancements and strategic direction.
Investors and researchers will find updates on clinical trial progress, regulatory milestones, and strategic collaborations with industry partners. The resource covers Nurix’s innovative pipeline, including BTK degraders for oncology and CBL-B inhibitors for immune modulation, alongside financial developments and operational updates.
Content is organized to highlight therapeutic innovations, scientific publications, and partnership announcements, ensuring stakeholders stay informed about Nurix’s progress in advancing oral small molecule therapies. Bookmark this page for real-time updates on Nurix’s pioneering work in E3 ligase modulation and protein homeostasis.
Nurix Therapeutics will present new data on their selective BTK degrader, NX-5948, at the European Hematology Association Congress (EHA2024) from June 13-16, 2024, in Madrid, Spain, and virtually.
The data, from an ongoing Phase 1a/b study, show a 70% overall response rate in 10 heavily pretreated CLL patients with resistance mutations to BTK inhibitors. The responses are deepening with longer treatment duration, and all responses are ongoing as of January 2024.
The presentation will also include additional data at higher dose levels and longer treatment durations. Nurix will host a webcast conference call on June 16 following the presentation.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) will participate in the RBC Capital Markets Global Healthcare Conference. Arthur T. Sands, M.D., Ph.D., Nurix's CEO, will be in a fireside chat on May 14, 2024. The event will be webcast live and accessible via the Investors section of the Nurix website.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
